LCID
Lucid Group, Inc.
LCID offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
LEVI
Levi Strauss & Co.
LEVI has the edge over LCID overall, supported by lower modeled downside.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LEVI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
LEVI's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
LEVI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $18.30 | -24% |
| Forward | 15x | $24.04 | — |
| Fair | 16x | $23.57 | -1.9% |
| Current | 16x | $24.04 | — |
| Expensive | 38x | $55.97 | +133% |
Historical ranges are pointers, not guarantees.
LEVI's PE is in its fair range at 16x. If earnings grow as analysts expect, today's price would be 15x next year's earnings.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LEVI Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for LEVI, with profitability improving.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
LEVI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.57 | +5.2% |
| Q3 2026 | $1.49 | -2% |
| Q2 2026 | $1.61 | +58% |
| Q1 2026 | $1.56 | +75% |
| Q4 2025 | $1.45 | +179% |
| Q3 2025 | $1.52 | +311% |
| Q2 2025 | $1.02 | +200% |
| Q1 2025 | $0.89 | +197% |
| Q4 2024 | $0.52 | -16% |
LEVI has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over LEVI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
LEVI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +4.3% |
| Q2 2026 | $1.6B | +8% |
| Q1 2026 | $1.7B | +14% |
| Q4 2025 | $1.8B | -4% |
| Q3 2025 | $1.5B | +1.8% |
| Q2 2025 | $1.4B | +0.3% |
| Q1 2025 | $1.5B | -2% |
| Q4 2024 | $1.8B | +12% |
LEVI's revenue has picked up after three years of holding roughly level: $1.6B last quarter, up 4.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +3 points |
| Q2 2026 | 7.8% | +0.4 points |
| Q1 2026 | 11% | -1.2 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 11% | +8.8 points |
| Q2 2025 | 7.5% | +5.9 points |
| Q1 2025 | 13% | +13 points |
| Q4 2024 | 12% | +2.3 points |
LEVI has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
LEVI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $44.3M | +$83.7M |
| Q2 2026 | $230.9M | +58% |
| Q1 2026 | $152.1M | +$166.2M |
| Q4 2025 | $215.7M | -6.9% |
| Q3 2025 | -$39.4M | -1813% |
| Q2 2025 | $146M | -34% |
| Q1 2025 | -$14.1M | -107% |
| Q4 2024 | $231.6M | +14% |
LEVI has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
LEVI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +991K shares |
| 1 year | -2.2% | -8.9M shares |
| 3 years | -2.6% | -10.4M shares |
| 5 years | -5.4% | -22.5M shares |
| Available history | -5.2% | -21.4M shares |
LEVI has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $500,000 |
| Q1 2025 | $30M |
| Q4 2024 | $30.4M |
LEVI hasn't bought back shares in the past year.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LEVI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.4x | Very low |
| Q4 2025 | 0.3x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.7x | Very low |
LEVI's net debt is less than a year of its operating earnings (EBITDA).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
LEVI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.3 | Neutral |
| Stochastic | 71.3 | Neutral |
LEVI's weekly RSI is 61 (neutral) and its Stochastic is 71 (neutral).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
LEVI PE vs Consumer Cyclical Sector
| Metric | LEVI | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 18x | 10% below |
| PE % | 50 | 47 | 3 pts above |
LEVI is trading at 16x earnings, a 10% discount to the Consumer Cyclical sector's median of 18x.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
LEVI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.2 | 14% above |
| 20 week MA | $22.1 | 8.7% above |
| 50 week MA | $21.8 | 10% above |
| 100 week MA | $20.3 | 18% above |
| 200 week MA | $18.7 | 29% above |
LEVI has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
LEVI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.3 | $20.6 | +7.1% |
| 2021 | $20.6 | $24.6 | +19% |
| 2022 | $24.6 | $15.5 | -37% |
| 2023 | $15.5 | $16.5 | +6.8% |
| 2024 | $16.5 | $17.2 | +3.9% |
| 2025 | $17.2 | $21.1 | +23% |
| 2026 YTD | $21.1 | $24.0 | +14% |
LEVI has the edge over LCID on returns for 2026, with the stronger performance.